Clinical Trial

Groundbreaking Study Finds Natural Formulation by MDbio – The Doctors BrandTM Significantly Improves Sleep, Anxiety, Stress, and Overall Well-being

Radicle Science studied MDSleep in one of history’s largest clinical trials on a supplement brand’s sleep formulation.Los Angeles, CA, Oct.…

9 months ago

Relievant Medsystems Announces Positive Coverage Policy for the Intracept Procedure from Anthem Blue Cross and Blue Shield

Expands access to vertebrogenic pain treatment for 36 million patientsMINNEAPOLIS, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company…

9 months ago

Cannabix’s MSBS Marijuana Breathalyzer Technology Advances Quantification of THC in Breath

Cannabix Technologies Inc. Cannabix Technologies MSBS and BCU Figures 1 and 2 VANCOUVER, British Columbia, Oct. 03, 2023 (GLOBE NEWSWIRE)…

9 months ago

Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent…

9 months ago

ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference

BLOOMFIELD HILLS, Mich, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company…

9 months ago

Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial

Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose…

9 months ago

Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers

WATERTOWN, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,…

9 months ago

Femasys Inc. MDSAP Surveillance Audit Successfully Completed

– Femasys demonstrates compliance with harmonized regulatory requirements for Australia, Brazil, Japan, Canada and the USA – – Femasys is committed…

9 months ago

Ethos Discovery and Gallant Therapeutics Collaborate on Study Evaluating Gallant’s Stem Cell Therapy in Pugs with Necrotizing Meningoencephalitis (NME), also referred to as Pug Dog Encephalitis (PDE)

NME is a progressive, typically fatal autoimmune disease characterized by brain inflammation, that has no disease-modifying treatment options availableSAN DIEGO…

9 months ago